SCHEDULE: BlackRock Reports 1.9% Stake in Fate Therapeutics

BlackRock, Inc. has disclosed beneficial ownership of 2,194,284 shares, representing 1.9% of the outstanding common stock of Fate Therapeutics Inc., as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Fate Therapeutics Inc. common stock.
• As of June 30, 2026, BlackRock beneficially owns 2,194,284 shares.
• This ownership represents 1.9% of the total outstanding class of securities.
• BlackRock holds sole voting power and sole dispositive power over these shares.
• The filing clarifies that this ownership is held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It confirms a significant institutional investor's passive stake but provides no new operational or strategic information about Fate Therapeutics itself.

Positives

• BlackRock's investment indicates confidence in Fate Therapeutics' long-term prospects, as it is a significant institutional investor.
• The filing confirms BlackRock's substantial, albeit passive, stake, which can be seen as a vote of confidence in the company's underlying value.

Negatives

• The ownership stake of 1.9% is below the 5% threshold that typically triggers more detailed Schedule 13D filings, suggesting BlackRock is not seeking to influence control.
• The filing does not provide any specific operational or financial performance data for Fate Therapeutics, focusing solely on BlackRock's ownership.

Risks

• The filing does not explicitly mention any risks related to Fate Therapeutics' business operations or financial health.
• Potential future changes in BlackRock's investment strategy could lead to significant selling pressure if they decide to divest their stake.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Fate Therapeutics. It solely reports BlackRock's current ownership status.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "Various persons have the right to receive or the power to direct the dividends from, or the proceeds from the sale of, the common stock of FATE THERAPEUTICS INC. No one person's interest in the common stock of FATE THERAPEUTICS INC is more than five percent of the total outstanding common shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large asset managers like BlackRock are common and typically indicate passive investment stakes. The 1.9% ownership suggests BlackRock is a significant institutional investor in the biotechnology sector, specifically in companies like Fate Therapeutics focused on cell therapy, but not an activist shareholder.

Stakeholder Impact

• Shareholders: The filing confirms BlackRock's substantial investment, which can lend credibility to the company, but the passive nature of the stake means no immediate impact on share price is expected from this filing alone.
• Employees: Continued investment by major institutions can provide a sense of stability and confidence in the company's future.
• Creditors: A stable institutional investor base can be viewed positively by creditors, indicating a degree of financial backing.

Next Steps

• BlackRock will continue to hold its shares in Fate Therapeutics Inc. unless it decides to change its investment strategy.
• Fate Therapeutics Inc. will continue its operations and disclosures as usual, with BlackRock as a significant, passive shareholder.

Key Dates

Keywords

Schedule 13G, BlackRock, Fate Therapeutics, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management